Natalizumab in the pediatric MS population: results of the Italian registry
Article 2015 en
Authors
AG
Angelo Ghezzi
LM
Lucia Moiola
CP
Carlo Pozzilli
Abstract
1 min read
A relevant reduction of relapse rate and EDSS was observed during NA treatment, compared to pre-treatment period. No evidence of disease activity (NEDA) occurred in 58% of cases.
Clara Grazia Chisari, Maria Pia Amato, Alessia Di Sapio, Matteo Foschi, Pietro Iaffaldano, Matilde Inglese, Salvatore Lo Fermo, Alessandra Lugaresi, Giacomo Lus, Nerina Mascoli, Sara Montepietra, Ilaria Pesci, R. Quatrale, Giuseppe Salemi, Valentina Torri Clerici, Rocco Totaro, Paola Valentino, Massimo Filippi, Francesco Patti
Filippo Martinelli Boneschi, Marco Rovaris, Kenneth P. Johnson, Aaron Miller, Jerry S. Wolinsky, David Ladkani, Galia Shifroni, Gıancarlo Comı, Massimo Filippi
Riccardo Saccardi, Massimo Filippi, Maria Pia Sormani, Massimo Di Gioia, Alberto Bosi, Paolo Di Bartolomeo, Amedea Donelli, Francesca Gualandi, Angelo Guerrasio, Giorgio La Nasa, Pietro Maggi, Alberto M. Marmont, Federico Papineschi, Luisa Vuolo, Maria Annunziata Rocca, Gianluigi Mancardi
Discussion(0)
No comments yet. Be the first to comment.